US Brand Name(s): Prolia, Xgeva
Use in Cancer Treatment
Denosumab is authorized to treat the following conditions:
- Bone tumor with a giant cell tumor that cannot be removed surgically. It is prescribed for adults and adolescents whose bones have reached the end of their growth.
- Malignancy-related hypercalcemia that worsened after bisphosphonate treatment
The Xgeva brand of denosumab has been authorized for these applications.
Denosumab has been approved for the following uses:
- Multiple myeloma and solid cancers that have metastasized (spread) to bone can cause broken bones and other bone issues. The Xgeva brand of denosumab has been authorized for this purpose.
Denosumab has also been authorized for increasing bone mass in people who are at a high risk of fracturing a bone. It’s used to treat the following cancers:
- Breast cancer in women who are using an aromatase inhibitor.
- Men on androgen deprivation treatment get prostate cancer.
The Prolia brand of denosumab has been authorized for these purposes.
Denosumab is also being researched for the treatment of various cancers and diseases.
A humanized monoclonal antibody with antiosteoclast action directed against the receptor activator of nuclear factor kappa beta ligand (RANKL). Denosumab binds to RANKL and prevents it from interacting with RANK, a receptor found on the surfaces of osteoclast cells, resulting in decreased osteoclast activity, decreased bone resorption, and a potential increase in bone mineral density. The protein RANKL, which is expressed by osteoblastic cells, is involved in osteoclastic differentiation and activation.
Denosumab Information on MedlinePlus – A summary of key information regarding this medication in layman’s terms, which may contain the following:
- cautions about this medicine,
- what it’s used for and how it’s used,
- what you should tell your doctor before taking it,
- what you should know about it before using it,
- other drugs that might interact with it, and
- possible negative effects
Drugs are frequently investigated to see whether they can assist treat or prevent conditions other than those for which they have been authorized. Only authorized uses of the medication are covered by this patient information leaflet. Much of the material, though, might also apply to authorized uses that are being investigated.